The veterinary-grade antigen concentrate designated CDV-API-VG-2025 is supplied as a monovalent live attenuated canine distemper virus lyophilizate prepared in a closed aseptic processing line. The product is standardised for downstream conversion into tablets, injections, capsules, powders, granules, premix, and solutions, but it is not a finished vaccine: it contains no sterile diluent, preservative, adjuvant, or oral protective coating. The freeze-dried cake is dispensed in Type I borosilicate glass vials under vacuum or nitrogen at a nominal antigen mass per vial that is reported on the batch certificate. The product code identifies the lyophilized antigen concentration, the 2025 process version, and the veterinary-grade quality system; separate product codes apply to prequalified parenteral-grade and oral-grade streams.

The enveloped paramyxovirus particle is 150–250 nm in diameter and carries haemagglutinin and fusion glycoproteins on a lipid envelope. The API retains measurable infectivity only when protected from pH below 6.0, from temperatures above 37 °C for more than 2 h in liquid form, and from residual moisture above 5.0% w/w in the dried cake. These boundaries are not excipient recommendations but process constraints; the formulator must treat the API as a heat-labile and oxidation-sensitive particulate antigen. Published stability data for this specific lyophilized configuration are limited beyond the manufacturer’s accelerated stability program; therefore, every new dosage form requires virus titration after each unit operation.

Propagation is performed in a defined canine-derived cell line under serum-free culture conditions. The harvest is clarified by depth filtration at 0.65 µm and concentrated by tangential-flow ultrafiltration with a 500 kDa membrane. The antigen concentrate is formulated in a sucrose-phosphate-glutamate stabiliser to a batch-specific titre commonly in the range 7.0–9.0 log10 TCID50 per mL before lyophilization. A 0.22 µm sterilising-grade filter is not used after virus addition because the enveloped virus particle and any virus aggregates may be retained; sterility is achieved by filtration of the stabiliser and aseptic virus seeding. The production sequence is consistent with the master seed and working seed requirements of 9 CFR 113.306 and Ph. Eur. 0451.

What release criteria apply to lyophilized CDV antigen concentrate under 9 CFR 113.306 and Ph. Eur. 0451?

Release testing divides into identity, purity, safety, and potency panels. Identity is confirmed by virus neutralisation or by monoclonal antibody immunofluorescence against CDV haemagglutinin. Potency is quantified by titration on Vero cells expressing canine SLAM/CD150; the titre is expressed as log10 TCID50 per dose-equivalent mass or per millilitre after reconstitution. Safety tests include sterility by membrane filtration using soybean-casein digest and thioglycollate media, mycoplasma culture on agar and broth, and endotoxin by kinetic chromogenic LAL. The table below lists control boundaries that are typical for veterinary-grade lyophilized live-virus antigen concentrates; the batch certificate values remain authoritative for this product.

During commercial lyophilization, filled vials are loaded into a chamber with a shelf area of 0.4 m² and a condenser capacity of 20 kg ice per cycle. Product temperature during primary drying is maintained at −30 °C to −25 °C for 24 h under a chamber pressure of 100–200 µbar. Secondary drying is performed at +20 °C for 12 h or until residual moisture is below the release limit. Vial heat transfer varies by shelf position; edge vials can dry up to 15% faster than centre vials, and the resulting titre difference can reach 0.3 log10 TCID50 per vial if the batch is not homogenised. The API is therefore blended by combining cake fragments from stratified shelf positions before final QC sampling.

Batch-to-batch titre variance in production freeze-drying with staggered shelf loading

Production-scale experience shows that the main drift in release titre is not bulk harvest variation but lyophilizer loading geometry. In a run with 1,800 vials distributed across three shelves, the centre-to-edge moisture gradient can be 0.8% w/w to 1.5% w/w across the tray. Vials in the centre retain higher moisture and exhibit slower vapour flux; therefore, their collapse risk is greater when shelf temperature is ramped to 0 °C too early. The current process uses a controlled ramp of 0.5 °C/min from −40 °C to −20 °C, followed by a 4 h hold. A viral titre loss of more than 1.0 log10 TCID50 is observed if the product temperature exceeds the glass transition temperature of the sucrose-phosphate-glutamate matrix; the glass transition temperature for this stabiliser system is approximately −22 °C in the frozen state. Product-specific data should be generated for each lyophilizer because published data for this exact formulation are limited.

When tablet and capsule forms are selected instead of parenteral administration

The API is not stable in a conventional compressed tablet unless the matrix provides moisture, oxygen, and acid protection. For tablet cores, direct compression is preferred over wet granulation because aqueous granulation at RH 60% or higher can reduce titre by more than 1.5 log10 TCID50 within 30 min. A dry granulation process using roller compaction at a roll pressure of 4–6 kN/cm² is acceptable only if the compact is milled through a 1.0 mm screen and immediately blended with mannitol and a stabilising polymer. Enteric coating with methacrylic acid copolymer dispersion is necessary if the tablet must pass through the stomach; gastric pH of 1.2–2.0 in fasted dogs disrupts the viral envelope within 5 min. Coating thickness should be controlled to 6–8 mg/cm² and polymer dissolution tested according to Ph. Eur. 2.9.3.

Hypromellose capsules are preferred over hard gelatin capsules because gelatin can introduce moisture and aldehyde crosslinking. The capsule fill weight is adjusted to deliver a target antigen mass equivalent of 25 mg of lyophilate; actual titre per capsule is confirmed by reconstitution and TCID50 titration. At a compression force of 8 kN using 7 mm round punches, disintegration time of the tablet core in 37 °C water is 8–12 min. Above 12 kN, matrix densification reduces water ingress and prolongs disintegration beyond 30 min, but virus titre after dissolution remains within 0.5 log10 of the uncompressed powder at 10 kN.

Liquid, granule, premix, and solution handling boundaries

For injection solutions, the lyophilized cake is reconstituted in sterile water for injection or a stabiliser diluent to a final volume of 1.0 mL per dose. Reconstituted suspension should be used within 4 h when stored at 2–8 °C; longer hold times result in titre loss of 0.2 log10 TCID50 per hour after 6 h. Do not heat the solution above 37 °C, do not sonicate, and do not pass through a 0.22 µm sterilising filter. A 1.2 µm low-protein-binding depth filter may be used if visual particulates are present, but filter validation must demonstrate no titre reduction greater than 0.1 log10.

For powders and premixes, the API is blended with lactose, mannitol, or maltodextrin at a ratio of 1:9 to 1:99 depending on the target final dose. The mixing vessel must be pre-conditioned at 20–25 °C and RH below 40% for at least 2 h. Zinc oxide and ferrous sulfate are incompatible in premixes because transition metal ions at concentrations above 10 mg/kg can catalyse lipid oxidation of the viral envelope. When the API is dissolved as an oral solution, the diluent must be buffered to pH 6.5–7.5 with citrate or phosphate. The solution should be protected from light because ultraviolet exposure at 254 nm for 45 min can inactivate enveloped virus by more than 3.0 log10. Glycerol at 10% v/v can be included as a cryoprotectant for frozen liquid formulations, but repeated freeze-thaw cycles beyond 2 cycles are not recommended.

How does the live attenuated CDV API differ from inactivated whole-virus or recombinant CDV antigen streams?

The principal difference is that the live attenuated API replicates in the host after administration, inducing both antibody and cell-mediated immunity at a lower antigen mass than inactivated whole-virus antigen. Inactivated CDV vaccines rely on adjuvants and require two doses; they are more stable in liquid formulation but may produce a Th2-biased response. Recombinant CDV antigen streams, such as those produced in baculovirus or plant systems, carry only the haemagglutinin or fusion glycoprotein and are non-infectious, but they do not present the full complement of viral antigens. A subunit or recombinant API is therefore less likely to be affected by existing maternal antibody interference, but may require a higher antigen mass per dose. The live attenuated veterinary-grade API is incompatible with chemical sterilisation, organic solvents, and long aqueous hold times, whereas inactivated antigen streams tolerate a wider pH range of 5.8–8.0. No single metric can substitute for immunogenicity studies under VICH GL44 or field efficacy trials conducted in the target breed and age group.

A formulator selecting between these antigen streams must align the dosage form with the target species, maternal antibody status, and route; the live attenuated API is the only stream suitable for replication-competent oral or mucosal delivery in dogs, but it imposes the narrowest processing window and requires cold-chain integrity from lyophilizer to final administration.